WallStSmart
PPBT

Purple Biotech

NASDAQ: PPBT · HEALTHCARE · BIOTECHNOLOGY

$3.85
-3.88% today

Updated 2026-06-05

Market cap
$2.79M
P/E ratio
0.00
P/S ratio
58.08x
EPS (TTM)
$3,226.00
Dividend yield
52W range
$3 – $29
Volume
0.1M

Purple Biotech (PPBT) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-269.45%
ROA
-19.60%
Debt/equity
0.02x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2013$-2.63M
2014$-5.25M
2015$-4.20M
2016$-12.13M
2017$100000.00$-12.18M100.00%-11,966.00%-12,177.00%
2018$1.00M$-5.20M100.00%-782.60%-520.00%
2019$1.00M$-5.85M99.99%-715.60%-585.00%
2020$1.00M$-28.00M99.99%-1,323.90%-2,799.90%
2021$-320000.00$-18.38M0.02%5,604.38%5,745.00%
2022$-910000.00$-21.67M0.01%2,483.85%2,381.10%
2023$195804.00$-19880.00-0.10%-11,374.13%-10.15%
2024$0.00$-7.24M
2025$0.00$-26.39M

Frequently asked questions

How much free cash flow does PPBT generate?

PPBT produced $-5.54M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PPBT's balance sheet healthy?

PPBT holds $8.72M in cash and equivalents against — in long-term debt, on $9.71M of shareholder equity. That debt is best read against the cash flow the business throws off each year.